Connect Biopharma is trading 6.01% up now at $2.47 after reporting second-quarter results with $2.8 million in collaboration revenue, versus minimal expectations, from a Simcere regulatory milestone.
- Completed enrollment in Phase 2 Seabreeze STAT asthma and COPD studies; topline results are expected in September 2026.
- Cash of $31.5 million is expected to fund operations for at least one year.
- The earnings-driven catalyst appears stronger than broader risk-on sentiment, while rising major indexes may provide additional support.